Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murugabaskar Balan

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
The Journal of Biological Chemistry|December 25, 2013
A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocationMurugabaskar Balan, Soumitro Pal
The Journal of Biological Chemistry|July 26, 2020
Correction: A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocationMurugabaskar Balan, Soumitro Pal
Clinics in Laboratory Medicine|February 3, 2019
Signaling Molecules in Posttransplantation CancerMurugabaskar Balan, Samik Chakraborty, Soumitro Pal
Clinical & Developmental Immunology|December 23, 2011
Interferon lambda: a new sword in cancer immunotherapyAhmed Lasfar, Walid Abushahba, Murugabaskar Balan, et al.
Scientific Reports|July 21, 2017
Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growthMurugabaskar Balan, Samik Chakraborty, Evelyn Flynn, et al.
Redox Biology|October 28, 2023
A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stressLaxminarayan Rawat, Murugabaskar Balan, Yuzuru Sasamoto, et al.
Frontiers in Oncology|December 5, 2019
Editorial: Tumor Microenvironment and Resistance to Current TherapiesAhmed Lasfar, Murugabaskar Balan, Karine A Cohen-Solal, et al.
Plos One|December 17, 2020
Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cellsYasaman Hamedani, Samik Chakraborty, Akash Sabarwal, et al.
Cancers|July 9, 2020
A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune EscapeAkash Sabarwal, Samik Chakraborty, Simran Mahanta, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|May 9, 2021
Metabolic reprogramming in renal cancer: Events of a metabolic diseaseSamik Chakraborty, Murugabaskar Balan, Akash Sabarwal, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The Journal of Biological Chemistry|December 25, 2013
A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocationMurugabaskar Balan, Soumitro Pal
The Journal of Biological Chemistry|July 26, 2020
Correction: A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocationMurugabaskar Balan, Soumitro Pal
Clinics in Laboratory Medicine|February 3, 2019
Signaling Molecules in Posttransplantation CancerMurugabaskar Balan, Samik Chakraborty, Soumitro Pal
Clinical & Developmental Immunology|December 23, 2011
Interferon lambda: a new sword in cancer immunotherapyAhmed Lasfar, Walid Abushahba, Murugabaskar Balan, et al.
Scientific Reports|July 21, 2017
Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growthMurugabaskar Balan, Samik Chakraborty, Evelyn Flynn, et al.
Redox Biology|October 28, 2023
A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stressLaxminarayan Rawat, Murugabaskar Balan, Yuzuru Sasamoto, et al.
Frontiers in Oncology|December 5, 2019
Editorial: Tumor Microenvironment and Resistance to Current TherapiesAhmed Lasfar, Murugabaskar Balan, Karine A Cohen-Solal, et al.
Plos One|December 17, 2020
Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cellsYasaman Hamedani, Samik Chakraborty, Akash Sabarwal, et al.
Cancers|July 9, 2020
A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune EscapeAkash Sabarwal, Samik Chakraborty, Simran Mahanta, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|May 9, 2021
Metabolic reprogramming in renal cancer: Events of a metabolic diseaseSamik Chakraborty, Murugabaskar Balan, Akash Sabarwal, et al.
Pageof 3